Exagen (NASDAQ:XGN) Stock: Insider Jorey Chernett Purchases 8,500 Shares

Exagen Inc. (NASDAQ:XGN) major shareholder Jorey Chernett purchased 8,500 shares of Exagen stock in a transaction on Monday, November 9th. The stock was bought at an average price of $6.35 per share, with a total value of $53,975.00. Following the completion of the acquisition, the insider directly owned 2,618,540 shares of the company’s stock, valued at approximately $16,627,729. This trade represents a 0.33% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Jorey Chernett also recently made the following trade(s):

• On Friday, November 6th, Jorey Chernett sold 11,265 shares of Exagen stock. The shares were sold at an average price of $6.14, for a total transaction of $69,167.10.
• On Tuesday, November 10th, Jorey Chernett acquired 7,085 shares of Exagen stock. The shares were bought at an average price of $5.26 per share, for a total transaction of $37,267.10.
• On Monday, October 19th, Jorey Chernett acquired 14,000 shares of Exagen stock. The shares were bought at an average price of $7.46 per share, for a total transaction of $104,440.00.

Exagen Price Performance

XGN stock opened at $5.03 on Thursday. The stock has a market capitalization of $121.85 million, a PE ratio of -6.71 and a beta of 2.25. The company’s 50-day moving average is $7.84 and its 200-day moving average is $5.13. The company has a debt-to-equity ratio of 1.96, a current ratio of 3.18 and a quick ratio of 3.18. Exagen Inc. has a 1 year low of $2.59 and a 1 year high of $9.73.

Exagen (NASDAQ:XGN) last issued its earnings results on Tuesday, November 10th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.07). Exagen had a negative net margin of 25.14% and a negative return on equity of 123.63%. The firm had revenue of $18.42 million during the quarter, compared to analyst estimates of $18.34 million. Equities research analysts expect that Exagen Inc. will post -0.69 EPS for the current fiscal year.

Hedge Funds Weigh In On Exagen

A number of hedge funds have recently bought and sold shares of XGN. GSA Capital Partners LLP bought a new stake in shares of Exagen in the 2nd quarter worth $998,000. Flputnam Investment Management Co. purchased a new stake in shares of Exagen in the second quarter valued at about $1,343,000. Man Group plc bought a new position in shares of Exagen during the second quarter valued at about $778,000. FourWorld Capital Management LLC lifted its position in shares of Exagen by 61.2% during the first quarter. FourWorld Capital Management LLC now owns 439,950 shares of the company’s stock valued at $1,320,000 after purchasing an additional 166,950 shares in the last quarter. Finally, BlackRock Inc. bought a new position in shares of Exagen during the second quarter valued at about $663,000. 75.25% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the company. BTIG Research restated a “buy” rating and set a $9.00 price objective on shares of Exagen in a report on Wednesday. TD Cowen upped their target price on Exagen from $10.00 to $11.00 and gave the stock a “buy” rating in a research report on Tuesday, October 13th. B. Riley Financial initiated coverage on Exagen in a report on Friday, September 11th. They issued a “buy” rating and a $12.00 target price on the stock. Canaccord Genuity Group cut their target price on Exagen from $11.00 to $9.00 and set a “buy” rating on the stock in a report on Wednesday. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Exagen in a research report on Wednesday, November 4th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $9.88.

Top Exagen Stories

Here are a few of the latest stories about XGN:

• Positive Sentiment: Exagen reiterated its 2026 revenue outlook of $72 million to $75 million and remains on track to launch its myositis offering in early 2027. A major shareholder’s recent purchases also exceeded his reported sale in the cited transactions, a modest supportive signal. Insider transaction report
• Neutral Sentiment: BTIG reaffirmed its Buy rating and $9 target. Canaccord also kept a Buy rating but cut its target from $11 to $9, tempering the positive analyst outlook. Canaccord analyst rating
• Negative Sentiment: Q3 adjusted loss of $0.25 per share missed analyst expectations of roughly $0.18–$0.19. Operating expenses increased and the operating loss widened to $4.4 million from $3.1 million a year earlier; cash also fell to $28.1 million from $35.7 million a year earlier. These results highlight continued losses and cash-use concerns despite revenue growth. Q3 earnings report

About Exagen

Exagen Inc. is a commercial-stage diagnostic company focused on improving the diagnosis and management of autoimmune and rheumatic diseases. The company develops and commercializes blood tests that help physicians identify autoimmune disease, distinguish among related conditions and monitor disease activity over time. Its principal product family is AVISE, which includes the AVISE CTD and AVISE Lupus tests, as well as monitoring and specialty tests used in the evaluation of systemic lupus erythematosus and other connective-tissue diseases.